Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase

AAV-AAG Latent enzyme delivery vector for Pompe disease · University of Florida

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase, covering 2017-11-17 to 2017-11-17. Get the full timeline:

Most recent: Clinical Trial Update: Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease [Phase 1, Phase 2]

See pricing